Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mather

Showing results (351-360 of 504) with videos related to

Pageof 51
Sort By:
Diabetes|January 15, 2008
Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention ProgramKieren J Mather, Tohru Funahashi, Yuji Matsuzawa, et al.
Diagnostics (Basel, Switzerland)|November 6, 2019
Advanced Heart Failure and End-Stage Heart Failure: Does a Difference ExistPaolo Severino, Paul J Mather, Mariateresa Pucci, et al.
Cancer Research|September 1, 1987
Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administrationB G Ward, S J Mather, L R Hawkins, et al.
Diabetes, Obesity & Metabolism|August 14, 2025
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesJulio Rosenstock, Deborah A Robins, Kevin L Duffin, et al.
Lancet (London, England)|June 27, 2023
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyJuan P Frias, Stanley Hsia, Sarah Eyde, et al.
Basic Research in Cardiology|May 29, 2016
Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonismDaniel J Sassoon, Adam G Goodwill, Jillian N Noblet, et al.
Diabetes Care|October 9, 2025
Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With TirzepatideCyrielle Caussy, Kenneth Cusi, Julio Rosenstock, et al.
Lancet (London, England)|November 9, 2025
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trialLiana K Billings, Stanley Hsia, Harold Bays, et al.
Cancer Immunology, Immunotherapy : CII|April 15, 1999
Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigenL M Stewart, S Young, G Watson, et al.
Journal of Clinical Microbiology|December 17, 2009
Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trialA Sargent, A Bailey, A Turner, et al.
Pageof 51

Showing results (351-360 of 504) with videos related to

Sort By:
Pageof 51
Diabetes|January 15, 2008
Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention ProgramKieren J Mather, Tohru Funahashi, Yuji Matsuzawa, et al.
Diagnostics (Basel, Switzerland)|November 6, 2019
Advanced Heart Failure and End-Stage Heart Failure: Does a Difference ExistPaolo Severino, Paul J Mather, Mariateresa Pucci, et al.
Cancer Research|September 1, 1987
Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administrationB G Ward, S J Mather, L R Hawkins, et al.
Diabetes, Obesity & Metabolism|August 14, 2025
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesJulio Rosenstock, Deborah A Robins, Kevin L Duffin, et al.
Lancet (London, England)|June 27, 2023
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyJuan P Frias, Stanley Hsia, Sarah Eyde, et al.
Basic Research in Cardiology|May 29, 2016
Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonismDaniel J Sassoon, Adam G Goodwill, Jillian N Noblet, et al.
Diabetes Care|October 9, 2025
Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With TirzepatideCyrielle Caussy, Kenneth Cusi, Julio Rosenstock, et al.
Lancet (London, England)|November 9, 2025
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trialLiana K Billings, Stanley Hsia, Harold Bays, et al.
Cancer Immunology, Immunotherapy : CII|April 15, 1999
Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigenL M Stewart, S Young, G Watson, et al.
Journal of Clinical Microbiology|December 17, 2009
Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trialA Sargent, A Bailey, A Turner, et al.
Pageof 51